Article
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Cancer discovery - 1 May 2012
Vivanco Igor, Robins H Ian, Rohle Daniel, Campos Carl, Grommes Christian, Nghiemphu Phioanh Leia, Kubek Sara, Oldrini Barbara, Chheda Milan G, Yannuzzi Nicolas, Tao Hui, Zhu Shaojun, Iwanami Akio, Kuga Daisuke, Dang Julie, Pedraza Alicia, Brennan Cameron W, Heguy Adriana, Liau Linda M, Lieberman Frank, Yung W K Alfred, Gilbert Mark R, Reardon David A, Drappatz Jan, Wen Patrick Y, Lamborn Kathleen R, Chang Susan M, Prados Michael D, Fine Howard A, Horvath Steve, Wu Nian, Lassman Andrew B, DeAngelis Lisa M, Yong William H, Kuhn John G, Mischel Paul S, Mehta Minesh P, Cloughesy Timothy F, Mellinghoff Ingo K
Abstract excerpt
UNLABELLED: Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR kinase domain (KD) mutations, GBMs respond poorly to the EGFR inhibitor erlotinib. Using RNAi, we show that GBM cells carrying EGFR EC mutations display EGFR addiction. In contrast to KD mutants found in lung cancer,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.